NeuBase Therapeutics, Inc.
NBSE · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $2 | $3,166 | $6,205 | $6,274 |
| - Cash | $12,570 | $14,747 | $13,845 | $17,386 |
| + Debt | $5,335 | $5,474 | $5,620 | $5,762 |
| Enterprise Value | -$7,233 | -$6,107 | -$2,020 | -$5,350 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$250 | -$304 | -$300 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$1,571 | -$3,142 | -$3,784 | -$3,396 |
| % Margin | – | – | – | – |
| Net Income | -$1,821 | -$3,447 | -$4,093 | -$4,369 |
| % Margin | – | – | – | – |
| EPS Diluted | -660.26 | -2.04 | -2.4 | -3.04 |
| % Growth | -32,265.7% | 15% | 21.1% | – |
| Operating Cash Flow | -$2,003 | -$3,644 | -$3,448 | -$5,688 |
| Capital Expenditures | $0 | -$0 | -$13 | -$50 |
| Free Cash Flow | -$2,003 | -$3,644 | -$3,461 | -$5,738 |